Direct Selective Laser Trabeculoplasty to reduce glaucoma medications

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm, open-label study at a single site using DSLT delivered with 120 shots, 400 µm spot size, and 1.8 mJ fixed energy applied at the limbus over 2.4 seconds. The primary endpoint is change in medication count at 6 months versus baseline, with secondary endpoints including absolute and percent IOP reduction, complete success rate without medication increase, proportion of eyes needing medication at 6 months, and need for secondary surgical interventions. Participants will be followed at 1, 3, and 6 months with IOP measured by calibrated Goldmann applanation tonometry. Adults on 1–3 topical ocular hypotensive agents with IOP ≤21 mmHg and a diagnosis of POAG or ocular hypertension are enrolled, excluding those with prior glaucoma surgery, recent cataract surgery, secondary glaucomas, or other significant ocular comorbidities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients scheduled to undergo DSLT treatment in one or both eyes.

  * Diagnosis of ocular hypertension or primary open angle glaucoma (POAG).
* Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg.

Exclusion Criteria:

* Previous glaucoma surgeries/interventions:

  * Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).
* Patients who have undergone cataract surgery within the prior 2 years.
* Secondary glaucoma:

  * Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.
* Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.

Where it's running

• The Eye Institute of West Florida
  Largo, Florida, United States Recruiting

Study contacts

• Principal investigator: Neel Desai, MD — The Eye Institute of West Florida
• Study coordinator: Renee Bondurant
• Email: Renee.Bondurant@eyespecialist.com
• Phone: 727-450-4668

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nanodropper microdrop delivery for primary open-angle glaucoma and ocular hypertension

  This test will see if Nanodropper microdrops of glaucoma medicines lower eye pressure as well as standard eye drops for adults with primary open-angle glaucoma or ocular hypertension.

  Recruiting 59th Medical Wing · Lackland Air Force Base, Texas · NCT05844384

• G01 Eye Drops for Glaucomatous Optic Neuropathy

  This trial tests whether G01 Eye Drops can help people with open-angle glaucoma who also have optic nerve injury.

  Recruiting at 9 sites Phase 2 Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. · Beijing, Beijing Municipality and 8 other locations · NCT07777861

• TFC-003: a new eye drop combo for open-angle glaucoma and ocular hypertension

  This study tests whether TFC-003, alone or in slight revisions, can safely lower eye pressure in adults with open-angle glaucoma or ocular hypertension who aren’t yet at their target pressure.

  Recruiting Phase 3 Kukje Pharma · Seongnam · NCT07662759

• Additive Physical Activity for Hypothyroidism in Older Women with Glaucoma and Fatty Liver

  We’re testing whether adding a treadmill-based exercise program to standard thyroid treatment helps improve health in older women who have subclinical hypothyroidism, glaucoma, and fatty liver.

  Recruiting Cairo University · Dokki, Giza Governorate · NCT07599241

• Imaging the effect of Netarsudil on the eye’s drainage system in glaucoma and ocular hypertension

  This study tests whether netarsudil eye drops change the trabecular meshwork’s structure compared with placebo in adults with ocular hypertension or open-angle glaucoma.

  Recruiting Phase 4 Indiana University · Bloomington, Indiana · NCT07588152

• Lifestyle changes plus nightly CPAP for glaucoma in people with sleep apnea

  This test checks whether adding a low-calorie diet and regular walking to nightly CPAP lowers eye pressure in people with high‑pressure open‑angle glaucoma who also have obstructive sleep apnea and obesity.

  Recruiting Cairo University · Giza, Dokki · NCT07447011

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.